A clinical trial conducted by NIH researchers found that PRGN-2012, an experimental gene therapy, may effectively treat recurrent respiratory papillomatosis (RRP), a condition caused by HPV types 6 and 11 that leads to noncancerous tumors in the respiratory tract. The phase 1/2 trial included 35 adults, with positive outcomes showing 18 patients needing no further procedures after one year. Follow-up over 22 months indicated lasting effects in some patients, while side effects remained mild. The research aims to offer an alternative to the repetitive surgeries currently used to manage RRP.
A clinical trial led by NIH has shown that PRGN-2012 gene therapy may be an effective treatment for recurrent respiratory papillomatosis, a debilitating HPV-related condition.
In a phase 1/2 trial, 35 adults with RRP were treated with PRGN-2012; 18 did not need further papilloma removal procedures within a year post-treatment.
Collection
[
|
...
]